What happened
SUPERIOR trial evaluates sacubitril/valsartan for preventing post-ablation atrial fibrillation recurrence in hypertensive patients.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Why the trial?
Does sacubitril/valsartan prevent recurrence of atrial fibrillation after catheter ablation in patients with hypertension?
Does sacubitril/valsartan prevent recurrence of atrial fibrillation after catheter ablation in patients with hypertension?
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward SUPERIOR's result, from named public quotes (n=0). As of Oct 22, 2026.
Sacubitril/valsartan for preventing recurrence of atrial fibrillation after catheter ablation in patients with hypertension: a multicenter, randomized controlled trial (SUPERIOR)
Sacubitril/valsartan for preventing recurrence of atrial fibrillation after catheter ablation in patients with hypertension: a multicenter, randomized controlled trial (SUPERIOR). Session: LBS.04. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
No takes yet. Share an insight, caveat, or question.
Bao et al. (2026) studied this question. Sacubitril/valsartan is being evaluated in the SUPERIOR randomized trial for preventing atrial fibrillation recurrence after catheter ablation in patients with hypertension, with results pending.